Observational Study of Efficacy and Safety of Travogen Cream and Travocort Cream in the Treatment of Mycoses
Launched by LEO PHARMA · Jul 23, 2008
Trial Information
Current as of May 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of skin mycosis
- Exclusion Criteria:
- • Allergies to study medication
About Leo Pharma
LEO Pharma is a global pharmaceutical company dedicated to developing innovative therapies for dermatological and critical care conditions. With a strong focus on research and development, LEO Pharma aims to improve the lives of patients through advanced treatments and a commitment to high-quality standards. The company collaborates with healthcare professionals and stakeholders to address unmet medical needs and drive scientific progress in the field. Through its clinical trials, LEO Pharma seeks to enhance therapeutic options and provide effective solutions for patients suffering from skin diseases and other related health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
St Petersburg, , Russian Federation
Patients applied
Trial Officials
Bayer Study Director
Study Director
Bayer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials